Literature DB >> 27138056

Progression of postural control and gait deficits in Parkinson's disease and freezing of gait: A longitudinal study.

Griet Vervoort1, Aniek Bengevoord2, Carolien Strouwen3, Esther M J Bekkers4, Elke Heremans5, Wim Vandenberghe6, Alice Nieuwboer7.   

Abstract

BACKGROUND AND AIMS: The relationship between impaired postural control and freezing of gait (FOG) in Parkinson's disease (PD) is still unclear. Our aim was to identify if postural control deficits and gait dysfunction progress differently in freezers compared to non-freezers and whether this relates to FOG development.
METHODS: 76 PD patients, classified as freezer (n = 17) or non-freezer (n = 59), and 24 controls underwent a gait and postural control assessments at baseline and after 12 months follow-up. Non-freezers who developed FOG during the study period were categorized as FOG converters (n = 5). Gait was analyzed during walking at self-preferred pace. Postural control was assessed using the Mini-BESTest and its sub-categories: sensory orientation, anticipatory, reactive and dynamic postural control.
RESULTS: Mini-BESTest scores were lower in PD compared to controls (p < 0.001), and in freezers compared to non-freezers (p = 0.02). PD has worse anticipatory (p = 0.01), reactive (p = 0.02) and dynamic postural control (p = 0.003) compared to controls. Freezers scored lower on dynamic postural control compared to non-freezers (p = 0.02). There were no baseline differences between converters and non-converters. Decline in postural control was worse in PD compared to controls (p = 0.02) as shown by a greater decrease in the total Mini-BESTest score. Similar patterns were found in freezers (p = 0.006), who also showed more decline in anticipatory (p < 0.001) and dynamic postural control (p = 0.02) compared to non-freezers. FOG converters had a greater decline in the total Mini-BESTest (p = 0.005) and dynamic postural control scores (p = 0.04) compared to non-converters. Gait outcomes showed no significant differences in any of the analyses.
CONCLUSION: FOG is associated with more severe decline in postural control, which can be detected by the clinical Mini-BESTest.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Balance; Conversion; Freezing of gait; Gait; Parkinson's disease; Progression

Mesh:

Year:  2016        PMID: 27138056     DOI: 10.1016/j.parkreldis.2016.04.029

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  12 in total

1.  Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson's disease.

Authors:  Chioma Anidi; Johanna J O'Day; Ross W Anderson; Muhammad Furqan Afzal; Judy Syrkin-Nikolau; Anca Velisar; Helen M Bronte-Stewart
Journal:  Neurobiol Dis       Date:  2018-09-06       Impact factor: 5.996

2.  Low to moderate relationships between gait and postural responses in Parkinson disease.

Authors:  Ellen N Sutter; Katie J Seidler; Ryan P Duncan; Gammon M Earhart; Marie E McNeely
Journal:  J Rehabil Med       Date:  2017-06-28       Impact factor: 2.912

3.  The prevalence of freezing of gait in Parkinson's disease and in patients with different disease durations and severities.

Authors:  Hong-Liang Ge; Xiao-Yong Chen; Yuan-Xiang Lin; Ting-Juan Ge; Liang-Hong Yu; Zhang-Ya Lin; Xi-Yue Wu; De-Zhi Kang; Chen-Yu Ding
Journal:  Chin Neurosurg J       Date:  2020-05-14

4.  Automated freezing of gait assessment with marker-based motion capture and multi-stage spatial-temporal graph convolutional neural networks.

Authors:  Benjamin Filtjens; Pieter Ginis; Alice Nieuwboer; Peter Slaets; Bart Vanrumste
Journal:  J Neuroeng Rehabil       Date:  2022-05-21       Impact factor: 5.208

Review 5.  Pharmacological treatment in Parkinson's disease: Effects on gait.

Authors:  Katrijn Smulders; Marian L Dale; Patricia Carlson-Kuhta; John G Nutt; Fay B Horak
Journal:  Parkinsonism Relat Disord       Date:  2016-07-17       Impact factor: 4.891

6.  Freezing of Gait in Parkinson's Disease: Risk Factors, Their Interactions, and Associated Nonmotor Symptoms.

Authors:  David Gordon Lichter; Ralph Holmes Boring Benedict; Linda Ann Hershey
Journal:  Parkinsons Dis       Date:  2021-01-12

Review 7.  Gaps and roadmap of novel neuromodulation targets for treatment of gait in Parkinson's disease.

Authors:  Rubens Gisbert Cury; Nicola Pavese; Tipu Z Aziz; Joachim K Krauss; Elena Moro
Journal:  NPJ Parkinsons Dis       Date:  2022-01-11

Review 8.  Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes.

Authors:  Ashley Polhemus; Laura Delgado Ortiz; Gavin Brittain; Nikolaos Chynkiamis; Francesca Salis; Heiko Gaßner; Michaela Gross; Cameron Kirk; Rachele Rossanigo; Kristin Taraldsen; Diletta Balta; Sofie Breuls; Sara Buttery; Gabriela Cardenas; Christoph Endress; Julia Gugenhan; Alison Keogh; Felix Kluge; Sarah Koch; M Encarna Micó-Amigo; Corinna Nerz; Chloé Sieber; Parris Williams; Ronny Bergquist; Magda Bosch de Basea; Ellen Buckley; Clint Hansen; A Stefanie Mikolaizak; Lars Schwickert; Kirsty Scott; Sabine Stallforth; Janet van Uem; Beatrix Vereijken; Andrea Cereatti; Heleen Demeyer; Nicholas Hopkinson; Walter Maetzler; Thierry Troosters; Ioannis Vogiatzis; Alison Yarnall; Clemens Becker; Judith Garcia-Aymerich; Letizia Leocani; Claudia Mazzà; Lynn Rochester; Basil Sharrack; Anja Frei; Milo Puhan
Journal:  NPJ Digit Med       Date:  2021-10-14

Review 9.  Stepping up to meet the challenge of freezing of gait in Parkinson's disease.

Authors:  Simon Lewis; Stewart Factor; Nir Giladi; Alice Nieuwboer; John Nutt; Mark Hallett
Journal:  Transl Neurodegener       Date:  2022-05-01       Impact factor: 9.883

10.  Effectiveness of a Long-Term, Home-Based Aerobic Exercise Intervention on Slowing the Progression of Parkinson Disease: Design of the Cyclical Lower Extremity Exercise for Parkinson Disease II (CYCLE-II) Study.

Authors:  Jay L Alberts; Anson B Rosenfeldt; Cielita Lopez-Lennon; Erin Suttman; A Elizabeth Jansen; Peter B Imrey; Leland E Dibble
Journal:  Phys Ther       Date:  2021-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.